Loading clinical trials...
Loading clinical trials...
Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Chemotherapy- Refractory Wild Type RAS and BRAF Metastatic Colorectal Cancer
Conditions
Interventions
Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
Locations
21
China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Cancer hospital Chinese academy of medical sciences
Beijing, Beijing Municipality, China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
The Sixth Affiliated Hospital Of Sun Yat-sen University
Guangzhou, Guangdong, China
Start Date
February 12, 2018
Primary Completion Date
December 1, 2018
Completion Date
December 1, 2019
Last Updated
January 23, 2018
NCT06625775
NCT04657068
NCT06607458
NCT06820463
NCT07361003
NCT06792695
Lead Sponsor
Sinocelltech Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions